Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Nov;6(6):262-6.
doi: 10.1177/1758834014548187.

Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series

Andrew J Dooley  1 , Avinash Gupta  2 , Madhumita Bhattacharyya  3 , Mark R Middleton  4
Affiliations
Review

Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series

Andrew J Dooley et al. Ther Adv Med Oncol. 2014 Nov.

Abstract

The selective BRAF inhibitors, vemurafenib and dabrafenib, yield high response rates and improved overall survival in patients with BRAF V600E-mutant metastatic melanoma. Acquired drug resistance and drug toxicity are key challenges when using these drugs. We investigated whether vemurafenib toxicity could successfully be managed with intermittent dosing, and if its therapeutic efficacy could be maintained on intermittent dosing. Six patients with BRAF V600E-mutated metastatic melanoma were treated with an intermittent dosing regimen of vemurafenib. In three patients, toxicities were successfully managed with an intermittent dosing regimen. In the other three patients, intolerable toxicities continued on intermittent dosing. Our experience shows that intermittent dosing can successfully manage vemurafenib toxicities where continuous dosing at a reduced dose does not. Intermittent treatment improves drug tolerability and can achieve or maintain melanoma shrinkage. We recommend that in clinical practice, intermittent dosing should be considered as an alternative to dose reduction/termination in the management of vemurafenib toxicity.

Keywords: intermittent; melanoma; resistance; toxicity; vemurafenib.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflicts of interest in preparing this article.

References

    1. Adams R., Meade A., Seymour M., Wilson R., Madi A., Fisher D., et al. . (2011) Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 12: 642-653 - PMC - PubMed
    1. Blum J., Dieras V., Lo Russo P., Horton J., Rutman O., Buzdar A., et al. . (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92: 1759-1768 - PubMed
    1. Chapman P., Hauschild A., Robert C., Haanen J., Ascierto P., Larkin J., et al. . (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516 - PMC - PubMed
    1. Das Thakur M., Salangsang F., Landman A., Sellers W., Pryer N., Levesque M., et al. . (2013) Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494: 251-255 - PMC - PubMed
    1. Davies H., Bignell G., Cox C., Stephens P., Edkins S., Clegg S., et al. . (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954 - PubMed